Terms: = Brain cancer AND MDM2, HDM2, 4193, ENSG00000135679, HDMX, MGC71221, hdm2, Q00987
286 results:
1. The mdm2-p53 Axis Represents a Therapeutic Vulnerability Unique to Glioma Stem Cells.
Nakagawa-Saito Y; Mitobe Y; Togashi K; Suzuki S; Sugai A; Takenouchi S; Nakamura K; Sonoda Y; Kitanaka C; Okada M
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612758
[TBL] [Abstract] [Full Text] [Related]
2. Glioblastoma Therapy: Past, Present and Future.
Obrador E; Moreno-Murciano P; Oriol-Caballo M; López-Blanch R; Pineda B; Gutiérrez-Arroyo JL; Loras A; Gonzalez-Bonet LG; Martinez-Cadenas C; Estrela JM; Marqués-Torrejón MÁ
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473776
[TBL] [Abstract] [Full Text] [Related]
3. The development of a custom RNA-sequencing panel for the identification of predictive and diagnostic biomarkers in glioma.
Shirai Y; Ueno T; Kojima S; Ikeuchi H; Kitada R; Koyama T; Takahashi F; Takahashi K; Ichimura K; Yoshida A; Sugino H; Mano H; Narita Y; Takahashi M; Kohsaka S
J Neurooncol; 2024 Mar; 167(1):75-88. PubMed ID: 38363490
[TBL] [Abstract] [Full Text] [Related]
4. Genetic alterations that deregulate RB and PDGFRA signaling pathways drive tumor progression in IDH2-mutant astrocytoma.
Tateishi K; Miyake Y; Nakamura T; Iwashita H; Hayashi T; Oshima A; Honma H; Hayashi H; Sugino K; Kato M; Satomi K; Fujii S; Komori T; Yamamoto T; Cahill DP; Wakimoto H
Acta Neuropathol Commun; 2023 Nov; 11(1):186. PubMed ID: 38012788
[TBL] [Abstract] [Full Text] [Related]
5. Delivery versus Potency in Treating brain Tumors: BI-907828, a mdm2-p53 Antagonist with Limited BBB Penetration but Significant In Vivo Efficacy in Glioblastoma.
Zhang W; Vaubel RA; Oh JH; Mladek AC; Talele S; Zhang W; Waller KL; Burgenske DM; Sarkaria JN; Elmquist WF
Mol Cancer Ther; 2024 Jan; 23(1):47-55. PubMed ID: 37828724
[TBL] [Abstract] [Full Text] [Related]
6. KDM2B-Rearranged Soft Tissue Sarcomas Expand the Concept of BCOR-Associated Sarcoma.
Motoi T; Hirata M; Kukita Y; Satomi K; Tamura H; Adachi S; Matsushita Y; Horiguchi SI; Hishima T; Ikegami M; Okuma T; Tao K; Arakawa A; Ogawa C; Matsuda K; Ichimura K; Nakamura H; Mori T; Yoshida A
Mod Pathol; 2023 Nov; 36(11):100317. PubMed ID: 37634866
[TBL] [Abstract] [Full Text] [Related]
7. Designed novel nuclear localizing anticancer peptide targets p53 negative regulator mdm2 protein.
Mukherjee N; Bhunia D; Garai PK; Mondal P; Barman S; Ghosh S
J Pept Sci; 2024 Jan; 30(1):e3535. PubMed ID: 37580909
[TBL] [Abstract] [Full Text] [Related]
8. ROS1 Alterations as a Potential Driver of Gliomas in Infant, Pediatric, and Adult Patients.
Meredith DM; Cooley LD; Dubuc A; Morrissette J; Sussman RT; Nasrallah MP; Rathbun P; Yap KL; Wadhwani N; Bao L; Wolff DJ; Ida C; Sukhanova M; Horbinski C; Jennings LJ; Farooqi M; Gener M; Ginn K; Kam KL; Sasaki K; Kanagal-Shamanna R; Alexandrescu S; Brat D; Lu X
Mod Pathol; 2023 Nov; 36(11):100294. PubMed ID: 37532182
[TBL] [Abstract] [Full Text] [Related]
9. Tau protein binds to the P53 E3 ubiquitin ligase mdm2.
Sola M; Rendon-Angel A; Rojo Martinez V; Sgrignani J; Magrin C; Piovesana E; Cavalli A; Paganetti P; Papin S
Sci Rep; 2023 Jun; 13(1):10208. PubMed ID: 37353565
[TBL] [Abstract] [Full Text] [Related]
10. miR-3174 Is a New Tumor Suppressor MicroRNA That Inhibits Several Tumor-Promoting Genes in Glioblastoma.
Hanif F; Zhang Y; Dube C; Gibert MK; Saha S; Hudson K; Marcinkiewicz P; Kefas B; Guessous F; Abounader R
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298284
[TBL] [Abstract] [Full Text] [Related]
11. Single-cell molecular profiling using ex vivo functional readouts fuels precision oncology in glioblastoma.
Panovska D; Nazari P; Cole B; Creemers PJ; Derweduwe M; Solie L; Van Gassen S; Claeys A; Verbeke T; Cohen EF; Tolstorukov MY; Saeys Y; Van der Planken D; Bosisio FM; Put E; Bamps S; Clement PM; Verfaillie M; Sciot R; Ligon KL; De Vleeschouwer S; Antoranz A; De Smet F
Cell Mol Life Sci; 2023 May; 80(6):147. PubMed ID: 37171617
[TBL] [Abstract] [Full Text] [Related]
12. Study of
Biswas P; Bibi S; Yousafi Q; Mehmood A; Saleem S; Ihsan A; Dey D; Hasan Zilani MN; Hasan MN; Saleem R; Awaji AA; Fahmy UA; Abdel-Daim MM
Molecules; 2023 Mar; 28(7):. PubMed ID: 37049742
[TBL] [Abstract] [Full Text] [Related]
13. Selective protection of normal cells from chemotherapy, while killing drug-resistant cancer cells.
Blagosklonny MV
Oncotarget; 2023 Mar; 14():193-206. PubMed ID: 36913303
[TBL] [Abstract] [Full Text] [Related]
14. Expression and Clinical Significance of mdm2 in Non-Functioning PitNETs.
Yao X; Liu Q; Zhao S; Cheng R; Liu C; Zhang G
Medicina (Kaunas); 2023 Feb; 59(2):. PubMed ID: 36837574
[No Abstract] [Full Text] [Related]
15. Polymorphisms in
Morais de Castro E; Barbosa LV; Simoneti Fonseca A; Nagashima S; Busatta Vaz de Paula C; Zeni R; Panini do Carmo LA; Cavalli LR; Bleggi Torres LF; Senff Ribeiro A; de Noronha L; Machado-Souza C
ASN Neuro; 2023; 15():17590914231153481. PubMed ID: 36714975
[TBL] [Abstract] [Full Text] [Related]
16. EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection.
Capper D; Reifenberger G; French PJ; Schweizer L; Weller M; Touat M; Niclou SP; Euskirchen P; Haberler C; Hegi ME; Brandner S; Le Rhun E; Rudà R; Sanson M; Tabatabai G; Sahm F; Wen PY; Wesseling P; Preusser M; van den Bent MJ
Neuro Oncol; 2023 May; 25(5):813-826. PubMed ID: 36632791
[TBL] [Abstract] [Full Text] [Related]
17. Infiltrating gliomas with FGFR alterations: Histologic features, genetic alterations, and potential clinical implications.
Dono A; El Achi H; Bundrant BE; Goli PS; Zhu P; Ozkizilkaya HI; Esquenazi Y; Ballester LY
Cancer Biomark; 2023; 36(2):117-131. PubMed ID: 36530080
[TBL] [Abstract] [Full Text] [Related]
18. BI-907828, a novel potent mdm2 inhibitor, inhibits glioblastoma brain tumor stem cells in vitro and prolongs survival in orthotopic xenograft mouse models.
Hao X; Bahia RK; Cseh O; Bozek DA; Blake S; Rinnenthal J; Weyer-Czernilofsky U; Rudolph D; Artee Luchman H
Neuro Oncol; 2023 May; 25(5):913-926. PubMed ID: 36521007
[TBL] [Abstract] [Full Text] [Related]
19. Helicobacter pylori promotes epithelial-to-mesenchymal transition by downregulating CK2β in gastric cancer cells.
Lee SD; Jeong H; Hwang BR; Yu BM; Cho Y; Nam KT; Kim H; Lee YC
Biochim Biophys Acta Mol Basis Dis; 2023 Jan; 1869(1):166588. PubMed ID: 36404440
[TBL] [Abstract] [Full Text] [Related]
20. Quantitation of navtemadlin in human plasma and brain tissue by liquid chromatography-tandem mass spectrometry.
Kagan AB; Anders NM; Hemingway A; Lee EQ; Kelly KR; Lee HC; Xu-Welliver M; Piekarz R; Rudek MA
Biomed Chromatogr; 2022 Nov; 36(11):e5467. PubMed ID: 35895384
[TBL] [Abstract] [Full Text] [Related]
[Next]
